Implanon is a drug owned by Organon Usa Llc. It is protected by 1 US drug patent filed in 2017 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2030. Details of Implanon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9757552 | Applicator for inserting an implant |
Jul, 2030
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Implanon's patents.
Latest Legal Activities on Implanon's Patents
Given below is the list of recent legal activities going on the following patents of Implanon.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9757552 |
| Mail Post Card | 21 Aug, 2018 | US9757552 |
| Recordation of Patent Grant Mailed | 12 Sep, 2017 | US9757552 |
| Patent Issue Date Used in PTA Calculation | 12 Sep, 2017 | US9757552 |
| Email Notification | 24 Aug, 2017 | US9757552 |
| Issue Notification Mailed | 23 Aug, 2017 | US9757552 |
| Printer Rush- No mailing | 21 Aug, 2017 | US9757552 |
| Email Notification | 21 Aug, 2017 | US9757552 |
| Mailing Corrected Notice of Allowability | 21 Aug, 2017 | US9757552 |
| Pubs Case Remand to TC | 14 Aug, 2017 | US9757552 |
FDA has granted several exclusivities to Implanon. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Implanon, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Implanon.
Exclusivity Information
Implanon holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Implanon's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 31, 2014 |
Several oppositions have been filed on Implanon's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Implanon's generic, the next section provides detailed information on ongoing and past EP oppositions related to Implanon patents.
Implanon's oppositions filed in EPO
Implanon has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 11, 2019, by Holme Patent A/S. This opposition was filed on patent number EP06707783A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP18182632A | Jun, 2021 | Consilient Health Limited | Granted and Under Opposition |
| EP06707783A | Apr, 2019 | Holme Patent A/S | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Implanon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Implanon's family patents as well as insights into ongoing legal events on those patents.
Implanon's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Implanon's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 28, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Implanon Generics:
There are no approved generic versions for Implanon as of now.
About Implanon
Implanon is a drug owned by Organon Usa Llc. It is used for contraception. Implanon uses Etonogestrel as an active ingredient. Implanon was launched by Organon in 2006.
Market Authorisation Date:
Implanon was approved by FDA for market use on 17 July, 2006.
Active Ingredient:
Implanon uses Etonogestrel as the active ingredient. Check out other Drugs and Companies using Etonogestrel ingredient
Treatment:
Implanon is used for contraception.
Dosage:
Implanon is available in implant form for implantation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 68MG/IMPLANT | IMPLANT | Discontinued | IMPLANTATION |